Almac and TTP Labtech form alliance in fluorescence lifetime technology

09-Jan-2013 - United Kingdom

Almac and TTP Labtech announced the formation of an alliance in the field of fluorescence lifetime (FLT) technology to provide screening performance.

FLT as a reading modality offers a robust, antibody-free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library. Developed utilising experience in peptide engineering and chemical synthesis and design, Almac’s FLEXYTE™ assays harness potential of FLT to provide an efficient and economical platform for screening and profiling. The evolving assay platform offers solutions for many major therapeutic target classes including kinases, proteases, phosphatases, DUB and an increasing number of epigenetic targets.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances